Differential Analysis of Homocysteine and Uric Acid Levels in Patients with Cognitive Impairment Due to Parkinson’s Disease and Post-Stroke Conditions - Report - MDSpire
Advertisement
Differential Analysis of Homocysteine and Uric Acid Levels in Patients with Cognitive Impairment Due to Parkinson’s Disease and Post-Stroke Conditions
Clinical Report: Differential Analysis of Homocysteine and Uric Acid Levels
Overview
This study compares homocysteine and uric acid levels in patients with cognitive impairment due to Parkinson’s disease and post-stroke conditions. It identifies significant differences in biomarker levels and their correlation with cognitive function, suggesting distinct metabolic profiles between the two conditions.
Background
Cognitive impairment is a significant cause of disability in neurological diseases, particularly in Parkinson’s disease and post-stroke conditions. Understanding the metabolic differences between these conditions can enhance clinical diagnosis and intervention strategies. Identifying accessible biomarkers like homocysteine and uric acid may provide insights into disease mechanisms and patient management.
Data Highlights
Group
Homocysteine (μmol/L)
Uric Acid (μmol/L)
MMSE Correlation (r)
PD-CI
Higher (2.55, p = 0.032)
Lower (−34.66, p = 0.020)
−0.456 (p < 0.001)
PS-CI
Lower
Higher
−0.175 (p = 0.180)
Key Findings
PD-CI patients had significantly higher homocysteine levels compared to PS-CI patients.
Uric acid levels were significantly lower in the PD-CI group.
Homocysteine negatively correlated with cognitive function as measured by MMSE in both groups.
Low educational attainment and absence of hypertension were independently associated with PD-CI.
Uric acid levels did not show a significant association with MMSE scores in either group.
Clinical Implications
The distinct metabolic profiles observed in PD-CI and PS-CI patients highlight the importance of considering these differences in clinical assessments. Elevated homocysteine may serve as a potential biomarker for cognitive impairment in Parkinson's disease, while uric acid levels could provide additional insights for differential diagnosis.
Conclusion
This study underscores the metabolic differences between cognitive impairment due to Parkinson’s disease and post-stroke conditions, suggesting that homocysteine and uric acid levels may play a role in clinical differentiation. Further research is needed to validate these findings in prospective studies.
